Clinicopathological Features and Treatment Challenges in Triple Negative Breast Cancer Patients: A Retrospective Cohort Study

Amira ELWAN¹ ^(D), Aziza E. ABDELRAHMAN² ^(D), Ahmed A. ALNAGAR³ ^(D), Mohamed I ABDELHAMID⁴ ^(D), Nashwa NAWAR¹ ^(D)

Department of ¹Clinical Oncology and Nuclear Medicine, ²Pathology, ³Medical Oncology, ⁴General Surgery, Zagazig University, Faculty of Medicine, ZAGAZIG, EGYPT

ABSTRACT

Objective: As the genetic and molecular profiles of triple negative breast carcinoma (TNBC) are elucidated, multiple therapeutic targets have been produced. TNBC with less than 1% androgen receptor (AR) expression may respond to enzalutamide with greater response association in higher levels. A metronomic dose of capecitabine and docetaxel are effective developed drugs for angiogenic process inhibition. We aimed to demonstrate the treatment outcome of triple-negative breast cancer patients in correlation to their clinicopathological features.

Materials and Methods: A retrospective cohort study of 80 TNBC patients was conducted. The patients underwent proper observation with the reporting of their treatment and follow-up data. Patients with a metastatic disease, neoadjuvant chemotherapy, follow-up drop or data shortage were excluded from the survival analysis.

Results: The study results revealed a significant association between negative androgen expression and younger age \leq 35 years, premenopausal status, higher grade, extracapsular extension, lymphovascular invasion, Ki 67, and CA15-3 (p=0.003, 0.02, <0.001, 0.001, 0.027, 0.005, 0.009 respectively). The three-year overall survival (OS) in patients who received bicalutamide was better than those patients who received capecitabine or docetaxel but of no significance (p=0.46). The three-year disease free survival (DFS) was significantly better in the bicalutamide arm versus the other two groups (p=0.012).

Conclusions: We concluded that extended adjuvant antiandrogen such as bicalutamide and metronomic capecitabine are well tolerated with accepted compliance and affordability compared to docetaxel and are warranted for problem-solving and better DFS and OS in some TNBC patients.

Keywords: Triple negative breast cancer, Androgen receptor, Capecitabine, Bicalutamide

INTRODUCTION

Triple-negative breast cancer (TNBC) that represents 12-17% of all breast cancers (BC) is defined by less than 1% of the estrogen receptor (ER) and progesterone receptor expression, and normal human epidermal growth factor receptor 2 (HER2) gene copy number and expression (1). TNBCs have more aggressive behavior than non-TNBCs. Patients with TNBC tend to have higher relapse rates and probability of CNS and visceral metastases than those with non-TNBC (2).

Different genomic and molecular technique applications have revealed TNBC heterogeneity in the form of basal-like (BL), immunomodulatory (IM), mesenchymal (M), and luminal androgen receptor (LAR) subtypes, and each one demonstrates a unique pattern of gene expression. Because of the elucidated genetic and molecular profiles of TNBC,

(Turk Patoloji Derg 2021, 37:121-129)

Received: 30.09.2020 Accepted: 23.10.2020

multiple therapeutic targets have been produced and TNBCs are amenable for treatment intervention (3).

Anthracycline and taxane-based protocols of chemotherapy were considered as the mainstay treatment of TNBC patients (4). Treatment guidelines of early TNBC patients did not include platinum agents, but their use is explained in specific cases, such as those with a high risk of relapse and in need of rapid disease control, where the use of carboplatin was recommended for patients with known mutant BRCA; however, a carboplatin-based combination is one of the available protocols for adjuvant treatment nowadays (5).

Androgen receptors include 3 domains consisting of amino-terminal domain, DNA binding domain, and a carboxyl-terminal domain that functionally act with each other. The first one is the largest and responsible for the

Correspondence: Aziza E. ABDELRAHMAN Zagazig University Faculty of Medicine, Department of Pathology, ZAGAZIG, EGYPT E-mail: azaelsayed@gmail.com Phone: +0020 106 874 32 18

Copyright © 2021 The Author(s). This is an open-access article published by Federation of Turkish Pathology Societies under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.

activation of function domain AF1 that includes the tau 1 and tau 2 transcription activating units essential for androgen receptor activity. The amino-terminal domain contains a polyglutamine (CAG) sequence with various repetition numbers (6). Rebbeck et al. have discovered the relationship between patients carrying at least one AR allele with more than 28 CAG repeats and a significant risk of breast cancer (7).

Androgen receptor (AR) is expressed in 12-55% of TNBC cases (8-10). Some variation in expression frequency between studies is due to the different use of anti-AR antibodies or an assay cutoff difference (1% versus 10%). BC with less than 1% AR expression may respond to enzalutamide and may be associated with greater response in higher levels of AR expression (8). In AR-positive TNBC subtype patients, bicalutamide is well tolerated and could be proposed as an alternative to cytotoxic chemotherapy in such patients with better OS and DFS outcomes (11).

In comparison to hormone receptor-positive breast cancer, capecitabine has shown differential activity in TNBC in limited reported data (12). The proposal of metronomic chemotherapy is defined by the close and the regular intervals of chronic administration of low doses of cytotoxic drugs with no prolonged drug-free interruptions, in favor of lower toxicity and risk of drug-resistant tumor cell emergence in comparison to conventional administration (13). TNBC is considered a highly proliferative tumor with more enhanced angiogenesis that supports rapid growth and early metastasis, and tends to have high levels of vascular endothelial growth factor (VEGF). The metronomic dose of capecitabine is effective in TNBC as it leads to inhibition of the angiogenic process (14).

Docetaxel therapy has a significant role in both neoadjuvant and adjuvant management of triple negative breast cancer patients (15). Metronomic administration of docetaxel has achieved survival gains (16).

Compared to non-TNBC cases, TNBC cases are characterized by higher levels of VEGF and the blockade of angiogenesis will therefore lead to improving the outcomes in such patients. This was investigated in adjuvant phase III trials that evaluated the addition of one year of metronomic cyclophosphamide, methotrexate CM maintenance therapy (International Breast Cancer Study Group-22-00), as well as bevacizumab for one year proposed as standard chemotherapy (BEATRICE Study) (17). In this study, we aimed to demonstrate the outcome of triple-negative breast cancer patients treated with various strategies in correlation to their clinicopathological features.

MATERIAL and METHODS

Eighty TNBC patients were conducted to general surgery, pathology, clinical oncology, and medical oncology departments as a multidisciplinary team in a retrospective cohort study from January 2016 to January 2020. The patient data were collected from the patient's records with approval by the local ethics committee (Approval no: 6394-15-09-2020, Date: 15.09.2020). Focusing on the patient's clinical outcome post adjuvant treatment period as extending treatment. Patients with metastatic disease, neoadjuvant chemotherapy proposal, follow-up drop, and data shortage were excluded from the survival analysis. Included patients underwent proper observation with reporting of their treatment and follow-up data, besides the proper history and physical examinations. Full lab, chest x-ray, pelvic abdominal ultrasonography, mammography, breast ultrasound, CT chest, abdomen, and pelvis with contrast, CT brain or MRI with contrast were requested. A bone scan was requested according to the clinical conditions such as bone pain in the early stage and was performed in all local advanced and metastatic cases. Some patients underwent a PET scan. At the general surgery department, the patients underwent either a true-cut or excisional biopsy, breast conservation, or modified radical mastectomy. Eighty patients were proposed adjuvant chemotherapy and 71 patients out of 80 received adjuvant radiotherapy.

Immunohistochemistry

The staining was carried out using the polymer Envision detection system the Dako EnVision[™] kit (Dako, Copenhagen, Denmark). Tissue sections (3-5 µm) were deparaffinized in xylene and rehydrated in graded alcohol. To block endogenous peroxidase, slides were incubated for 10 min in 3% hydrogen peroxide. Dako target antigen retrieval solution (pH 6.0) was applied for 20 min. Afterwards, the slides were incubated for 60 min with the primary anti-ER antibody (clone D07, DAKO), anti-PR antibody (PR 636, Dako at 1:50 dilution); Polyclonal HER2 antibody in the Herceptin kit (HercepTest, DAKO); Ki67 antibody (clone MIB-1, 1:50 dilution; Dako); and Anti-Androgen receptor antibody [EPR1535 (2)] (ab133273). The reaction was visualized by incubating the sections with diaminobenzidine (DAB) for 15 min after which Mayer's hematoxylin was used

Interpretation of Immunohistochemical Staining

For ER and PR expression, moderate to strong nuclear staining in \geq 1% of the tumor cells was considered positive. Her2/neu was considered positive if at least 10% of tumor cells exhibited 3+ cell membrane staining. The cut-off point for Ki67 expression was 14%. AR expression was semiquantitatively scored using an H-score like the method described by Niemeier et al. An immunohistochemical score >10 was considered as a positive result (18).

We analyzed the extended adjuvant treatment after initially proposed protocols of chemotherapy \pm radiotherapy, which was reported in patient files and records. Hence, patients were followed in 3 groups: the first received bicalutamide (anti-androgen) in AR positive in 50 mg, with or without meals once daily for 2 years, and group 2 who had negative AR and received capecitabine 650 mg/ m² BID for one year, and group 3 patients who had unknown AR status and received docetaxel in a protocol of 15mg/ m² in weekly for 4 weeks to be escalated to 20 mg/m² once per week with accepted lab consideration for 6 months.

Statistical Analysis

Continuous variables were expressed as the mean \pm SD and median (range), and the categorical variables were expressed as a number (percentage). The percentages of categorical variables were compared using Pearson's Chisquare test or Fisher's exact test when appropriate. The trend of change in the distribution of relative frequencies between ordinal data was compared using the Chi-square test for trend. Overall Survival (OS) was calculated as the time from diagnosis to death or the most recent followup contact (censored). Disease-Free Survival (DFS) was calculated as the time from the date of surgery to the date of relapse or the most recent follow-up contact when patient was known to be relapse-free. Stratification of OS and DFS was done according to intention to treat (ITT). These timeto-event distributions were estimated using the method of Kaplan-Meier plot and compared using a two-sided exact log-rank test. All tests were two-sided. A p-value <0.05 was considered significant. All statistics were performed using SPSS 22.0 for windows (IBM Inc., Chicago, IL, USA).

RESULTS

Clinicopathological Features

The mean age at presentation was 42.60 ± 12.05 years. Most of the cases were grade III (56.3%) and 82.5 % showed lymph node metastasis. IDC of no special type was the most common histopathological type (65%). As regards the pathologic stage, 55% of the cases were T1 with lymphovascular invasion in 55% of the cases. The clinicopathological data of the cases enrolled in this study were summarized in (Table I).

The Relation Between Clinicopathological Features and Androgen Receptor IHC Staining

Positive androgen expression was noted in 26.3% of the studied cases (Figure 1A-C). Negative Androgen expression revealed strong association with younger age \leq 35 years, premenopausal status, higher grade, extracapscular extension, lympho-vascular emboli, Ki 67 and CA15-3 with p values (0.003, 0.02, <0.001, 0.001, 0.027, 0.005, 0.009 respectively) (Table II). Regarding to the toxicity of bicalutamide and capecitabine was shown in (Table II).

Toxicity Outcome

Bicalutamide was well tolerated as 17 (81%) patients out of 21 patients had shown no toxicity, only 2 patients showed grade (G) 2 hot flushes, one patient showed weight change in the form of increase in weight, only one patient suffered from G1 drowsness. 14 /27 patients (58.3%) had shown no toxicity of capecitabine proposal, 5(20.8%) patients were presented by G2 diarrhea, 3 patients (12.5%) presented by G1 hand pain, redness and swelling, only 2(8.3%) patients were presented by G2 nausia and vomiting. Regards docetaxel, more toxicity was observed only 7 (25.9%) who had no toxicity. Hematological toxicity was observed in 20 patients (74%), all are G1,2 except 2 patients showed G4 anemia, 8 (29.6%) patients were observed with G 1,2 pleural effusion



Figure 1: A) A case of TNBC grade 1 showing positive androgen expression (IHC; x400). **B)** A case of TNBC grade 2 showing positive androgen expression (IHC; x400). **C)** A case of TNBC grade 3 showing positive androgen expression (IHC; x400).

n % Characteristics n % Age (years) Stage		All patier	nts (N=80)	Characteristics	All patients (N=80)		
Age (years)StageMean \pm SD42.60 \pm 12.05Stage IB1316.3Median (Range)41(22–68)Stage IIB1822.5255 years3240Stage IIB1822.5255 years3240Stage IIB78.8Premenopausal status733.8Stage IIC911.3Postmenopausal4556.3Stage IIC911.3Postmenopausal810Ki-67Family historyHigh5366.366.3Positive1113.8Low2733.8Negative6986.3Andregen receptorType of surgeryPositive2126.343.8No91.3CEAGradeHigh4961.331.88.8-Grade II78.8Normal3138.8-Grade II78.8Normal3138.8-IDC5265RadiotherapyILC1012.5Yes7188.8Mized IDC & ILC1518.8Normal3116.3Present333.8ChemotherapyILC1012.5Yes7188.8Others33.8ChemotherapyNot reported78.8Mortally(Ne-72) <th>Characteristics</th> <th>n</th> <th>%</th> <th>- Characteristics –</th> <th>n</th> <th>%</th>	Characteristics	n	%	- Characteristics –	n	%	
Mean 2D 42.60 ± 12.05 Stage IB 13 16.3 Median (Range) 41 $(22-68)$ Stage IIA 15 18.8 235 years 32 40 Stage IIB 18 22.5 235 years 48 60 Stage IIB 7 8.8 Premenopausal staus Stage IIC 9 11.3 0 12.5 Perimenopausal 8 10 $Ki-67$ $Ki-67$ T 7 33.8 8 10 $Ki-67$ T 7 33.8 66.3 $70.38.8$ 70.38	Age (years)			Stage			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Mean ± SD	42.60	±12.05	Stage IB	13	16.3	
± 35 years 32 40 Stage IIB 18 22.5 >35 years 48 60 Stage IIIA 10 12.5 >35 years 48 60 Stage IIIA 10 12.5 Premenopausal status Stage IIIB 7 8.8 10 Postmenopausal 27 33.8 Stage IIV 8 10 Fermenopausal 8 10 Ki-67 T F Family history High 53 66.3 Androgen receptor T Positive 11 13.8 Low 27 33.8 Negative 69 86.3 Androgen receptor T 7 8.8 No 9 11.3 CEA T 5 6.3 Alge IIA 30 8 30 Grade I 7 8.8 Normal 31 38.8 S 64.3 Alge IIA 37 46.3 Grade II 7 8.8 Normal 31 35.3 S S S S S S S <td< td=""><td>Median (Range)</td><td>41</td><td>(22 - 68)</td><td>Stage IIA</td><td>15</td><td>18.8</td></td<>	Median (Range)	41	(22 - 68)	Stage IIA	15	18.8	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	≤35 years	32	40	Stage IIB	18	22.5	
Menopausal status Stage IIIB 7 8.8 Premenopausal 45 56.3 Stage IIC 9 11.3 Portmenopausal 27 33.8 Stage IV 8 10 Perimenopausal 8 10 K-67 53 66.3 Positive 11 13.8 Low 27 33.8 Negative 69 86.3 Androgen receptor 24 30 RIRM 46 57.5 Negative 24 30 RCS 25 31.3 Unknown 35 43.8 No 9 11.3 CEA T 30 Grade I 7 8.8 Normal 31 38.8 Grade II 28 35 CA 15-3 T T Grade II 28 35 CA 15-3 T T S8.8 Pathological subtype Normal 43 53.8 Pathological subtype Normal 43 53.8 Dick TLC 10 12.5 Yes 71 88.8 Pathological s	>35 years	48	60	Stage IIIA	10	12.5	
Premenopausal 45 56.3 Stage IIIC 9 11.3 Postmenopausal 27 33.8 Stage IV 8 10 Perimenopausal 8 10 Ki-67 11 13.8 Low 27 33.8 Positive 11 13.8 Low 27 33.8 66.3 Negative 69 86.3 Androgen receptor 7 33.8 7 33.8 No 9 11.3 CEA 24 30 RCS 25 31.3 Unknown 35 43.8 No 9 11.3 CEA	Menopausal status			Stage IIIB	7	8.8	
Postmenopausal 27 33.8 Stage IV 8 10 Perimenopausal 8 10 Ki-67	Premenopausal	45	56.3	Stage IIIC	9	11.3	
Perimenopausal 8 10 Ki-67 Family history High 53 66.3 Positive 11 13.8 Low 27 33.8 Negative 69 86.3 Androgen receptor Positive 21 26.3 Type of surgery Positive 21 26.3 30.8 40.5.5 30.8 30.8	Postmenopausal	27	33.8	Stage IV	8	10	
Family history High 53 66.3 Positive 11 13.8 Low 27 33.8 Negative 69 86.3 Androgen receptor 7 33.8 Type of surgery Positive 21 26.3 MRM 46 57.5 Negative 24 30 BCS 25 31.3 Unknown 35 43.8 No 9 11.3 CEA	Perimenopausal	8	10	Ki-67			
Positive 11 13.8 Low 27 33.8 Negative 69 86.3 Androgen receptor 7 26.3 Type of surgery Positive 21 26.3 MRM 46 57.5 Negative 24 30 BCS 25 31.3 Unknown 35 43.8 No 9 11.3 CEA Grade	Family history			High	53	66.3	
Negative 69 86.3 Androgen receptor Type of surgery Positive 21 26.3 MRM 46 57.5 Negative 24 30 BCS 25 31.3 Unknown 35 43.8 No 9 11.3 CEA T 31 38.8 Grade High 49 61.3 Grade II 28 35 CA 15-3 T 46.3 Grade II 28 35 CA 15-3 T 46.3 53.8 100 10 12.5 Yes 71 88.8 80 9 11.3 10 12.5 Yes 71 88.8 88.8 100 9 11.3 10 12.5 Yes 71 88.8 88.8 100 9 11.3 16.3 <t< td=""><td>Positive</td><td>11</td><td>13.8</td><td>Low</td><td>27</td><td>33.8</td></t<>	Positive	11	13.8	Low	27	33.8	
Type of surgery Positive 21 26.3 MRM 46 57.5 Negative 24 30 BCS 25 31.3 Unknown 35 43.8 No 9 11.3 CEA	Negative	69	86.3	Androgen receptor			
MRM 46 57.5 Negative 24 30 BCS 25 31.3 Unknown 35 43.8 No 9 11.3 CEA Grade High 49 61.3 Grade I 7 8.8 Normal 31 38.8 Grade II 28 35 CA 15-3 Grade II 43 53.8 S3.8 Gade II 43 53.8 S3.8 IDC 52 65 Radiotherapy III.3 Otherapy III.3 II.6.3 No 9 II.3 Otherapy III.3 II.6.3 No 9 II.3 No No 9 II.3 No III.3 II.6.3 No No III.3 II.6.3 No No III.3 II.6.3 No III.3 <	Type of surgery			Positive	21	26.3	
BCS 25 31.3 Unknown 35 43.8 No 9 11.3 CEA	MRM	46	57.5	Negative	24	30	
No 9 11.3 CEA Grade High 49 61.3 Grade I 7 8.8 Normal 31 38.8 Grade II 28 35 CA 15-3 Scalar	BCS	25	31.3	Unknown	35	43.8	
Grade High 49 61.3 Grade I 7 8.8 Normal 31 38.8 Grade II 28 35 CA 15-3	No	9	11.3	CEA			
Grade I 7 8.8 Normal 31 38.8 Grade II 28 35 CA 15-3	Grade			High	49	61.3	
Grade II 28 35 CA 15-3 Grade III 45 56.3 High 37 46.3 Pathological subtype Normal 43 53.8 IDC 52 65 Radiotherapy 10 13.8 53.8 IDC 10 12.5 Yes 71 88.8 Mixed IDC & ILC 15 18.8 No 9 11.3 Others 3 3.8 Chemotherapy 7 88.8 Extracapsular extension AC-Taxanes 54 67.5 Absent 40 50 Carboplatin+Taxanes 13 16.3 Not reported 7 8.8 Follow-up duration (months) 14.57 Absent 31 38.8 Median (Range) 36 (16 - 36) Present 44 55 Mortality (N=72) 16.7 Not reported 5 6.3 Alive 60 83.3 Lymphowascular invasion Ji 16.3 Absent 50 69.4 Not reported 5 6.3 A	Grade I	7	8.8	Normal	31	38.8	
Grade III 45 56.3 High 37 46.3 Pathological subtype Normal 43 53.8 IDC 52 65 Radiotherapy LLC 10 12.5 Yes 71 88.8 Mixed IDC & ILC 15 18.8 No 9 11.3 Others 3 3.8 Chemotherapy Extracapsular extension AC-Taxanes 54 67.5 Absent 40 50 Carboplatin+Taxanes 13 16.3 16.3 Present 33 41.3 EC-Taxanes 54 67.5 Absent 40 50 Carboplatin+Taxanes 13 16.3 Not reported 7 8.8 Follow-up duration (months) 44.57 Absent 31 38.8 Median (Range) 36 (16 - 36) Present 44 55 Mortality (N=72) Not reported 50 69.4 Not reported 5 6.3 Alive 60 83.3 Not Not reported 5 6.3	Grade II	28	35	CA 15-3			
Pathological subtype Normal 43 53.8 IDC 52 65 Radiotherapy	Grade III	45	56.3	High	37	46.3	
IDC 52 65 Radiotherapy ILC 10 12.5 Yes 71 88.8 Mixed IDC & ILC 15 18.8 No 9 11.3 Others 3 3.8 Chemotherapy 7 88.8 Extracapsular extension AC-Taxanes 54 67.5 Absent 40 50 Carboplatin+Taxanes 13 16.3 Present 33 41.3 EC-Taxanes 13 16.3 Not reported 7 8.8 Follow-up duration (months) 14.57 Absent 31 38.8 Median (Range) 36 (16 - 36) Present 44 55 Mortality (N=72) Not reported 5 6.3 Alive 60 83.3 Lymph node status Died 12 16.7 N0 14 17.5 Recurrence (N=72) N1mi 13 16.3 Absent 50 69.4 N1 26 32.5 Present 22 30.6 N2 <td>Pathological subtype</td> <td></td> <td></td> <td>Normal</td> <td>43</td> <td>53.8</td>	Pathological subtype			Normal	43	53.8	
ILC 10 12.5 Yes 71 88.8 Mixed IDC & ILC 15 18.8 No 9 11.3 Others 3 3.8 Chemotherapy -7 88.8 Extracapsular extension AC-Taxanes 54 67.5 Absent 40 50 Carboplatin+Taxanes 13 16.3 Present 33 41.3 EC-Taxanes 13 16.3 Not reported 7 8.8 Follow-up duration (months) -4.57 Lymphovascular invasion Mean \pm SD 33.80 ± 4.57 Absent 31 38.8 Median (Range) 36 (16 - 36) Present 44 55 Mortality (N=72) -72 Not reported 5 6.3 Alive 60 83.3 Lymph node status Died 12 16.7 N0 14 17.5 Recurrence (N=72) N1mi 13 16.3 Absent 50 69.4 N1 26 32.5 Present 22	IDC	52	65	Radiotherapy			
Mixed IDC & ILC 15 18.8 No 9 11.3 Others 3 3.8 Chemotherapy Extracapsular extension AC-Taxanes 54 67.5 Absent 40 50 Carboplatin+Taxanes 13 16.3 Present 33 41.3 EC-Taxanes 13 16.3 Not reported 7 8.8 Follow-up duration (months) ± 4.57 Lymphovascular invasion Mean \pm SD 33.80 ± 4.57 Absent 31 38.8 Median (Range) 36 $(16 - 36)$ Present 44 55 Mortality $(N=72)$ $Not reported$ 5 6.3 Alive 60 83.3 Lymph node status Died 12 16.7 $N0$ 14 17.5 Recurrence $(N=72)$ N1mi 13 16.3 Absent 50 69.4 N1 26 32.5 Present 22 30.6 N2 6 7.5 $N3$ 21 26.3 25 75 </td <td>ILC</td> <td>10</td> <td>12.5</td> <td>Yes</td> <td>71</td> <td>88.8</td>	ILC	10	12.5	Yes	71	88.8	
Others 3 3.8 Chemotherapy Extracapsular extension AC-Taxanes 54 67.5 Absent 40 50 Carboplatin+Taxanes 13 16.3 Present 33 41.3 EC-Taxanes 13 16.3 Not reported 7 8.8 Follow-up duration (months) 14.57 Lymphovascular invasion Median (Range) 36 (16 – 36) Present 44 55 Mortality (N=72) Not reported 5 6.3 Alive 60 83.3 Lymph node status Died 12 16.7 N0 14 17.5 Recurrence (N=72) N1mi 13 16.3 Absent 50 69.4 N1 26 32.5 Present 22 30.6 N2 6 7.5 14 16.3 14 17.5 N3 21 26.3 22 30.6 14 17 16 1	Mixed IDC & ILC	15	18.8	No	9	11.3	
Extracapsular extensionAC-Taxanes 54 67.5 Absent4050Carboplatin+Taxanes13 16.3 Present33 41.3 EC-Taxanes13 16.3 Not reported7 8.8 Follow-up duration (months)Lymphovascular invasionMean \pm SD 33.80 ± 4.57 Absent31 38.8 Median (Range) 36 $(16 - 36)$ Present4455Mortality $(N=72)$ Not reported5 6.3 Alive 60 83.3 Lymph node statusDied12 16.7 N014 17.5 Recurrence $(N=72)$ N1mi13 16.3 Absent 50 69.4 N126 32.5 Present 22 30.6 N2 6 7.5 75 75 75 N3 21 26.3 26.3 75 75 Tumor stage 71 44 55 72 75 T213 16.3 75 74 75 T3 16 20 75 74 75 T43 3.8 75 75 75	Others	3	3.8	Chemotherapy			
Absent4050Carboplatin+Taxanes1316.3Present3341.3EC-Taxanes1316.3Not reported78.8Follow-up duration (months)Lymphovascular invasionMean \pm SD33.80 \pm 4.57Absent3138.8Median (Range)36 $(16 - 36)$ Present4455Mortality $(N=72)$ Not reported56.3Alive6083.3Lymph node statusDied1216.7N01417.5Recurrence $(N=72)$ N1mi1316.3Absent5069.4N12632.5Present2230.6N267.5N32126.3Tumor stage7455T14455T21316.3T31620T433.83.8	Extracapsular extension			AC-Taxanes	54	67.5	
Present 33 41.3 EC-Taxanes 13 16.3 Not reported 7 8.8 Follow-up duration (months) Image: SD 33.80 ±4.57 Absent 31 38.8 Median (Range) 36 (16 - 36) Present 44 55 Mortality (N=72) Not reported 5 6.3 Alive 60 83.3 Lymph node status Died 12 16.7 N0 14 17.5 Recurrence (N=72) N1mi 13 16.3 Absent 50 69.4 N1 26 32.5 Present 22 30.6 N2 6 7.5 10 10 10 N2 26.3 21 26.3 11 11 N2 26.3 21 26.3 11 11 N3 21 26.3 11 11 11 11 11 11 11 11 11	Absent	40	50	Carboplatin+Taxanes	13	16.3	
Not reported 7 8.8 Follow-up duration (months) Lymphovascular invasion Mean \pm SD 33.80 \pm 4.57 Absent 31 38.8 Median (Range) 36 $(16 - 36)$ Present 44 55 Mortality $(N=72)$ Not reported 5 6.3 Alive 60 83.3 Lymph node status Died 12 16.7 N0 14 17.5 Recurrence $(N=72)$ N1mi 13 16.3 Absent 50 69.4 N1 26 32.5 Present 22 30.6 N2 6 7.5 N3 21 26.3 Tumor stage T 13 16.3	Present	33	41.3	EC-Taxanes	13	16.3	
Lymphovascular invasionMean \pm SD33.80 ± 4.57 Absent3138.8Median (Range)36 $(16 - 36)$ Present4455Mortality $(N=72)$ Not reported56.3Alive6083.3Lymph node statusDied1216.7N01417.5Recurrence $(N=72)$ N1mi1316.3Absent5069.4N267.57.533.8014N32126.32126.3Tumor stage7126.37.5711316.316.37.57.5T316207.47.5T433.87.87.5	Not reported	7	8.8	Follow-up duration (months)			
Absent 31 38.8 Median (Range) 36 (16 - 36) Present 44 55 Mortality (N=72) Not reported 5 6.3 Alive 60 83.3 Lymph node status Died 12 16.7 N0 14 17.5 Recurrence (N=72) N1mi 13 16.3 Absent 50 69.4 N1 26 32.5 Present 22 30.6 N2 6 7.5 75 75 75 75 75 75 N3 21 26.3 26.3 26.3 75<	Lymphovascular invasion			Mean ± SD	33.80	±4.57	
Present 44 55 Mortality (N=72) Not reported 5 6.3 Alive 60 83.3 Lymph node status Died 12 16.7 N0 14 17.5 Recurrence (N=72) N1mi 13 16.3 Absent 50 69.4 N1 26 32.5 Present 22 30.6 N2 6 7.5 N3 21 26.3 <	Absent	31	38.8	Median (Range)	36	(16 – 36)	
Not reported 5 6.3 Alive 60 83.3 Lymph node status Died 12 16.7 N0 14 17.5 Recurrence (N=72) N1mi 13 16.3 Absent 50 69.4 N1 26 32.5 Present 22 30.6 N2 6 7.5 N3 21 26.3 Tumor stage T T0 4 5 T1 44 55 5 T2 13 16.3 16.3 T3 16 20 7 T4 3 3.8	Present	44	55	Mortality	(N=72)		
Lymph node status Died 12 16.7 N0 14 17.5 Recurrence (N=72) N1mi 13 16.3 Absent 50 69.4 N1 26 32.5 Present 22 30.6 N2 6 7.5 N3 21 26.3 Tumor stage T0 4 5 <td>Not reported</td> <td>5</td> <td>6.3</td> <td>Alive</td> <td>60</td> <td>83.3</td>	Not reported	5	6.3	Alive	60	83.3	
N0 14 17.5 Recurrence (N=72) N1mi 13 16.3 Absent 50 69.4 N1 26 32.5 Present 22 30.6 N2 6 7.5 N3 21 26.3	Lymph node status			Died	12	16.7	
N1mi 13 16.3 Absent 50 69.4 N1 26 32.5 Present 22 30.6 N2 6 7.5 7.5 7.5 N3 21 26.3 7.5 7.5 Tumor stage 70 4 55 T2 13 16.3 7.5 T3 16 20 7.4 T4 3 3.8	N0	14	17.5	Recurrence	(N=72)		
N1 26 32.5 Present 22 30.6 N2 6 7.5 N3 21 26.3 Tumor stage 70 4 5 T1 44 55 T2 13 16.3 T3 16 20 T4 3 3.8	N1mi	13	16.3	Absent	50	69.4	
N2 6 7.5 N3 21 26.3 Tumor stage 70 4 5 T1 44 55 T2 13 16.3 T3 16 20 T4 3 3.8	N1	26	32.5	Present	22	30.6	
N3 21 26.3 Tumor stage T0 4 5 T1 44 55 T2 13 16.3 T3 16 20 T4 3 3.8	N2	6	7.5				
Tumor stage T0 4 5 T1 44 55 T2 13 16.3 T3 16 20 T4 3 3.8	N3	21	26.3				
To 4 5 T1 44 55 T2 13 16.3 T3 16 20 T4 3 3.8	Tumor stage						
Ti 44 55 T2 13 16.3 T3 16 20 T4 3 3.8	TO	4	5				
T2 13 16.3 T3 16 20 T4 3 3.8	T1	<u> </u>	55				
T2 10 10.0 T3 16 20 T4 3 3.8	T2	13	16.3				
T4 3 3.8	T3	16	20				
	T4	3	3.8				

Table I: Clinicopathological features, treatment, and outcome of triple-negative breast cancer patients.

IDC: Invasive ductal carcinoma, **ILC:** Invasive lobular carcinoma, **MRM:** Modified radical mastectomy, **BCS:** Breast conserving therapy Categorical variables were expressed as number (percentage); Continuous variables were expressed as mean ± SD & median (range).

Table II: Relationship between clinicopathological features and androgen receptor IHC staining.

	All P	atients		Androgen Receptor				
	(N:	=45)	Positiv	e (N=21)	Negativ	p-value		
Characteristics	n	%	n	%	n	%		
Age (years)								
≤35 years	19	42.2	4	21.1	15	78.9	0.002+	
>35 years	26	57.8	17	65.4	9	34.6	- 0.003‡	
Menopausal status								
Premenopausal	26	75	8	30.8	18	69.2		
Postmenopausal	17	37.8	11	64.7	6	35.3	0.028‡	
Perimenopausal	2	4.4	2	100	0	0		
Family history								
Positive	5	11.1	1	20	4	80	0.0501	
Negative	40	88.9	20	50	20	50	- 0.352‡	
Grade								
Grade I	5	11.1	4	80	1	20		
Grade II	19	42.2	14	73.7	5	26.3	<0.001§	
Grade III	21	46.7	3	14.3	18	85.7		
Pathological subtype		1007		1110	10			
IDC	27	60	14	51.9	13	48.1		
ILC	6	13.3	3	50	3	50	_	
Mixed IDC & ILC	10	22.2	3	30	7	70	- 0.695‡	
Others	2	4 4	1	50	1	50	_	
Extracapsular extension	<u> </u>	1.1	1	50	1	50		
Absent	25	55.6	17	68	8	32		
Present	20	44.4	4	20	16	80	- 0.001‡	
I vmphovascular invasion	20	11.1	1	20	10	00		
Absent	16	35.6	11	68.8	5	31.2		
Present	29	64.4	10	34.5	19	65.5	- 0.027‡	
Ivmph node status		01.1	10	0 1.0	17	00.0		
N0	2	4 4	2	100	0	0		
N1mi	24	53.3	10	41.7	14	58.3	_	
N1	<u></u>	89	10	25	3	75	0.9286	
N2	12	26.7	7	58.3	5	41 7	0.720 y	
N3	3	67		33.3	2	66.7	_	
Tumor stage	5	0.7	1	55.5	4	00.7		
T0	10	22.2	4	40	6	60		
<u>10</u> T1	8	17.8	5	62.5	3	37.5	_	
<u>11</u> T2	15	22.2		53.3	7		0 3246	
<u>12</u> T2	13	12.2	0	<u> </u>	2	40.7	0.3249	
<u>15</u> T4	6	13.3	4	00.7	6	100	_	
14 Stage	0	15.5	0	0	0	100		
Stage ID	0	17.9	F	62.5	2	27.5		
Stage ID Stage IIA	0	17.0		02.5	5	57.5	-	
Stage IIA Stage IIB	10	22.2		<u>40</u>	5	41.7	_	
Stage IID Stage IIIA	12	20.8	/	58.5	2	41./	- 0.082§	
Stage IIIA	<u> </u>	15.5	1	20	<u> </u>		_	
Stage IIIB	5	11.1	1	20	4	80	_	
Stage IIIC	4	8.9	0	0	4	100		
<u>NI-0/</u> Lliah	20	())	0	21	20	(0		
High		04.4	9	31		09	- 0.005‡	
	16	35.6	12	/5	4	25	-	
	27	()	10	27	17	(2)		
Hign Name al	27	60	10	37	17	63	- 0.113‡	
INORMAL CALLER 2	18	40	11	61.1	/	38.9	·	
<u>UA 15-3</u>	20		-	25	1.5			
High	20	44.4	5	25	15	75	- 0.009±	
Normal	25	55.6	16	64	9	36		

IDC: Invasive ductal carcinoma, ILC: Invasive lobular carcinoma.

Categorical variables were expressed as number (percentage); ‡ Chi-square test; § Chi-square test for trend; p<0.05 is significant. **Vol.** 37, No. 2, 2021; **Page** 121-129

Tout etter mus 61.	Anti-androgen arm (N=21)					
loxicity prome	n	%				
No toxicity	17	81				
Hot flashes	2	9.5				
Weight changes	1	4.8				
Drowsiness	1	4.8				

Table III: Toxicity profile of anti-androgen arm.

and 6 (22.2%) patients exhibited G1, 2 hepatotoxicity. All previous manifestations were well controlled by medical treatment and proper observations (Table III, IV).

Survival Outcome

The mean 3 years DFS was 35.3 months in patients who received bicalutamide, 33.16 months in patients received capecitabine, while in the docetaxel arm was 28.2 months

Table IV: Toxicity profile of capecitabine arm and docetaxel arm.

Torrigita angli	Capecitabin	e arm (N=24)	Docetaxel arm (N=27)		
Toxicity profile	n	%	n	%	
No toxicity	14	58.3	7	25.9	
Nausea & vomiting	2	8.3	0	0	
Hand pain redness & swelling	3	12.5	0	0	
Diarrhea	5	20.8	3	11.11	
Hematological	2	8.3	20	74	
Pleural effusion	0	0	8	29.6	
Hepatotoxicity	0	0	6	22.2	
Nephrological toxicity	0	0	3	11.11	

Table V: Comparison between anti-androgen arm, capecitabine arm, and docetaxel arm regarding survival outcome.

All patients (N=72)		Anti- androgen Arm (N=21)		Cape Arm	Capecitabine Arm (N=24)		Docetaxel Arm (N=27)		p ²	p ³	p ⁴
n	%	n	%	n	%	n	%				
50	69.4	19	90.5	19	79.2	12	44.4	0.001‡	0.422‡	0.001‡	0.011‡
22	30.6	2	9.5	5	20.8	15	55.6				
31.94 months		35.33 months		33.16	5 months 28.22 months		0.001+	0.264+	0.001+	0.012+	
(30.42	1-33.47)	(34.44	4-36.22)	(30.89	9-35.44)	(25.2	7-31.17)	0.0011	0.204†	0.0011	0.0121
98	3.6%	100%		10	100% 96.3%						
79	9.2%	100%		83	3.3%	59.3%					
69	9.4%	90).5%	79	9.2%	4	4.4%				
60	83.3	19	90.5	20	83.3	21	77.8	0.504‡	0.670‡	0.437‡	0.731‡
12	16.7	2	9.5	4	16.7	6	22.2				
34.91 months (34.29-35.53)		35.81 months (35.55-36.06)		34.83 months		34.29	34.29 months (33.06-35.52)		0.444†	0.212†	0.629†
				(33.68	(33.68-35.98)						
10	00%	1	00%	10	100%		00%				
10	00%	1	00%	100%		100%					
83	3.3%	90).5%	83	3.3%	7	7.8%				
	All p (N n 50 22 31.94 (30.4 (30.4) (All patients (N=72) n % 50 69.4 22 30.6 31.94 months ($30.41-33.47$) 98.6% 79.2% 69.4% 79.2% 69.4% 12 16.7 34.91 months ($34.29-35.53$) 100% 100% 83.3%	All patients (N=72) A and Arm n % n 50 69.4 19 22 30.6 2 31.94 months 35.33 ($30.41-33.47$) (34.44 98.6% 10 79.2% 10 60 83.3 19 12 16.7 2 34.91 months 35.81 ($34.29-35.53$) (35.51 100% 10 83.3% 90	Anti- androgen Arm (N=21) n % n % 50 69.4 19 90.5 22 30.6 2 9.5 22 30.6 2 9.5 31.94 months 35.33 months ($30.41-33.47$) $(34.44-36.22)$ 98.6% 100% 100% 79.2% 100% 69.4% 60 83.3 19 90.5 12 16.7 2 9.5 34.91 months 35.81 months ($35.55-36.06$) 100% 100% 100% 100% 33.3% 90.5% 90.5%	All patients (N=72) Anti- androgen Arm (N=21) Caped Arm n % n % n 50 69.4 19 90.5 19 22 30.6 2 9.5 5 31.94 months 35.33 months 33.16 $(30.41-33.47)$ $(34.44-36.22)$ (30.89) 98.6% 100% 10 10 79.2% 100% 83 69.4% 90.5% 79 60 83.3 19 90.5 20 12 16.7 2 9.5 4 34.91 months 35.81 months 34.83 $(34.29-35.53)$ $(35.55-36.06)$ (33.68) 100% 100% 10 10 10 10 83.3% 90.5% 83 83 83 83	All patients $(N=72)$ Anti- androgen Arm $(N=21)$ Capecitabine Arm $(N=24)$ n%n% 50 69.4 19 90.5 19 79.2 22 30.6 2 9.5 5 20.8 31.94 months 35.33 months 33.16 months $(30.41-33.47)$ $(34.44-36.22)$ $(30.89-35.44)$ 98.6% 100% 100% 79.2% 100% 83.3% 69.4% 90.5% 79.2% 60 83.3 19 90.5 20 83.3 12 16.7 2 9.5 4 16.7 34.91 months $(35.55-36.06)$ $(33.68-35.98)$ 100% 100% 100% 100% 100% 100% 100% 100% 100%	All patients $(N=72)$ Anti- androgen Arm $(N=21)$ Capecitabine Arm $(N=24)$ Dod Armn%n%n%n 50 69.4 19 90.5 19 79.2 12 22 30.6 2 9.5 5 20.8 15 31.94 months 35.33 months 33.16 months 28.22 $(30.41-33.47)$ $(34.44-36.22)$ $(30.89-35.44)$ (25.27) 98.6% 100% 100% 90.5 79.2% 100% 83.3% 59 69.4% 90.5% 79.2% 44 60 83.3 19 90.5 20 83.3 69.4% 90.5% 79.2% 44 60 83.3 19 90.5 20 83.3 69.4% 90.5% 79.2% 44 12 16.7 2 9.5 4 16.7 6 83.3 19 90.5 20 83.3 21 12 16.7 2 9.5 4 16.7 6 34.91 months 35.81 months 34.83 months 34.29 $(34.29-35.53)$ $(35.55-36.06)$ $(33.68-35.98)$ (33.00) 100% 100% 100% 100% 100% 100% 100% 100% 100%	All patients $(N=72)$ Anti- androgen Arm $(N=21)$ Capecitabine Arm $(N=24)$ Docetaxel Arm $(N=27)$ n%n%n%n%5069.41990.51979.21244.42230.629.5520.81555.6The second sec	All patients (N=72)Anti- androgen Arm (N=21)Capecitabine Arm (N=24)Docetaxel Arm (N=27) p^1 n%n%n%n%5069.41990.51979.21244.40.001‡2230.629.5520.81555.6 $(30.41-33.47)$ $(34.44-36.22)$ $(30.89-35.44)$ $(25.27-31.17)$ $0.001†$ 98.6%100%100%96.3% 9.5% 79.2% 44.4% $0.504\ddagger$ 6083.31990.520 83.3 21 77.8 $0.504\ddagger$ 1216.729.5416.76 22.2 34.91months35.81 34.83 months 34.29 $0.468†$ $(34.29-35.53)$ $(35.55-36.06)$ $(33.68-35.98)$ $(33.06-35.52)$ $0.468†$ 100%100%100%100%100% 100% 100%100%100%100%100% 100%	$\begin{array}{ c c c c c c c } All patients & Anti-androgen \\ Arm (N=21) & Arm (N=24) & Arm (N=27) & p^1 & p^2 \\ \hline n & \% & n & \% & n & \% & n & \% \\ \hline n & \% & n & \% & n & \% & n & \% \\ \hline s & s & s & s & s & s & s & s & s & s$	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

DFS: Disease free survival; OS: Overall survival

Continuous variables were expressed as mean (95%CI); categorical variables were expressed as number (percentage); \ddagger Chi-square test; \ddagger Log-rank test; \mathbf{p}^1 : p-value for the test between the three arms; \mathbf{p}^2 : p-value for the test between the anti-androgen arm and capecitabine arm; \mathbf{p}^3 : p-value for the test between anti-androgen and docetaxel arm; \mathbf{p}^4 : p-value for the test between capecitabine and docetaxel arm; p<0.05 is significant.

with significance P=0.001, better DFS was in the favor of bicalutamide administration. 3 years overall survival (OS) in patients who received bicalutamide better than those received capecitabine or docetaxcel but of no significance P=0.46 (Table V and Figure 2).

DISCUSSION

In the current study, we investigated the clinic-pathological criteria of triple-negative breast cancer patients who were conducted at our institutes at a specific period with high lighting on the proposed treatment such as antiandrogen (bicalutamide), capecitabine and docetaxel as an extended treatment

In this study we found that negative androgen expression had shown strong associations with younger age (\leq 35 years), premenopausal status, higher grade, extracapsular extension, lymphovascular invasion, Ki 67, and CA15-3, this was agreed with Farag et al. who studied the prevalence of androgen receptor expression in 90 patients of TNBC and the criteria of their clinic-pathology with no treatment proposal and revealed that AR negative patients was significantly associated with higher grade, higher stage, lymph node metastasis, distant metastasis, vascular, perineural invasion and high CA15-3 (19).

In our study 71/80, patients received adjuvant radiotherapy post adjuvant chemotherapy protocols such as AC-Taxens, carboplatin-Taxens, and EC-Taxens. Pal et al. confirmed the efficacy of combination treatment for TNBC patients (20). These findings were focused on evidence-based treatment recommendations (12,21,22). Furthermore, Chen et al. reported that radiotherapy post-mastectomy was associated with more prognosis improvement (23).

We agreed with Zakaria et al. who reported in their study with inclusion of 77 TNBC patient that the median age was 35.6 with a range of (19-63) and 21/77 patients (27.2%) were AR positive. AR expression was associated with high grade, high KI 67, positive nodal status and CA15-3. Along with her study, nobody died in AR positive patients, these patients received bicalutamide 50 mg once daily over 2 years as treatment duration with better 2 and 3 year OS which were 85% and 78% with p values of <0.001, 0.0005 respectively; bicalutamide was well-tolerated toxicity, no grade 3 and 4 adverse events in TNBC AR positive patients as well as 6 (28.57%) out of 21 patients presented in the form of 3 patients presented with nausea, two patients presented with breast fullness, tenderness, and hot flushes and only one patient who was presented by weight gain but with better OS and DFS outcome (11). In our study we found that bicalutamide was well tolerated as 17 (81%) patients out of 21 patients had shown no toxicity, only 2 patients showed G2 hot flushes, one patient showed weight change in the form of an increase in weight, and only one patient suffered from G1 drowsiness. These were all tolerated with more affordability. The mean 3-year DFS was 35.3 months in patients who received bicalutamide as extended treatment and better OS.

In our study, 13/27 patients (42.7%) had shown toxicity to capecitabine proposal, 5 (20.8%) patients presented with G2



Figure 2: Kaplan Meier plot of the studied arms, Left panel: Disease-free survival (A), Right panel: Overall survival (B).

diarrhea, 3 patients (12.5%) presented with G1 hand pain, redness and swelling, and only 2 (8.3%) patients presented with G2 nausea and vomiting while hematological toxicity was observed in 2 (8.3%) patients. In the docetaxel arm, unfortunately 20 (74%) patients exhibited hematological toxicity, and 8 (29.6%) patients complained of pleural effusion G1,2 where the pattern of toxicity was milder than reported by Abdelaziz et al. investigated 22 patients with TNBC who received metronomic capecitabine as extended treatment in non-metastatic condition, common toxicities were in the form of 2 patients presented by G1/ G2 hand foot syndrome and another 2 patients presented by G3/4 hand foot syndrome, 3 patients presented by G1/2 nausea and vomiting and 2 patients presented by G3 diarrhea, on the other hand hematological toxicity was observed in 5 patients in the form of anemia, in our study The 3 years DFS was 79.2%, 3 years OS 83.3% that was near to what was reported by Abdelaziz et al. as 3 years OS was 86.4%, while 3 year DFS was 81%.22; (24) in contrary to Alagizy et al., who studied 41 patients of TNBC and reported higher adverse effects of extended metronomic capecitabine after adjuvant chemotherapy such as G1 palmar- plantar erythrodysesthesia in 13 patients (31.7%); G 1 diarrhea in five patients (12.2%); and G1 vomiting in two patients (4.9%) with no G3/4 adverse effects. follow-up mean disease-free survival (DFS) was 42.4 months (95% CI). overall survival was 44.34 months (95% CI) with a lower incidence of recurrence and distant metastasis in comparison to other studies (25).

Abdelmaksoud et al. investigated the role of docetaxel in an extended treatment of 31 patients with triple negative breast cancer with a 3-year DFS and OS of 56.4 and 78.1, respectively, and a tolerable toxicity profile, and encouraged the use role of metronomic docetaxel for better survival gains (16).

TNBC patients may benefit from antiandrogen treatment as it is well tolerated with significantly lower toxicity than that of chemotherapy, and it can be proposed with other agent combinations (8,26-28). We agree with Locatelli et al. who stated that low dose maintenance capecitabine was an attractive approach with low cost, good tolerability, and manageability, especially in high-risk disease (29).

Inhibitors of such pathways as CDK4/6, PI3K, RAS, and MEK which command cell cycle progression, survival, proliferation, invasiveness, and drug escape can be optimally combined with an AR antagonist (30-32).

Our recommendation is to encourage further collaborative studies on a larger number of studied cases to gain more

accurate information in the absence of data bias with searching for novel, easy and cheap methods and aiming for proper treatment strategies and a proper patient selection guidance philosophy, targeting each triple-negative phenotype in different clinical scenarios.

In conclusion, progress in the treatment of TNBC remains an important challenge. The proposed bicalutamide shows better outcomes in favor of OS and toxicity with better tolerability. On the other hand, metronomic capecitabine is well tolerated with accepted patient compliance and affordability compared to docetaxel and is warranted for problem solving with better disease-free survival and overall survival in some triple-negative breast cancer patients.

CONFLICT of INTEREST

The authors declared that there is no conflict of interest.

AUTHORSHIP CONTRIBUTIONS

Concept: AE, HSM, Design: AEA, Data collection or processing: NN, Analysis or Interpretation: AE, Literature search: MIA, Writing: AAA, Approval: AE, AEA, NN, AAA, MIA

REFERENCES

- 1. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20:1071-82.
- 2. Dent R, Trudeau T, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429-34.
- Schmadeka R, Harmon BE, Singh M. Triple-negative breast carcinoma: Current and emerging concepts. Am J Clin Pathol. 2014;141:462-77.
- 4. Palma G, Frasci G, Chirico A, Esposito E, Siani C, Saturnino C, Arra C, Ciliberto G, Giordano A, D'Aiuto M. Triple negative breast cancer: Looking for the missing link between biology and treatments. Oncotarget. 2015;6(29):26560-74.
- Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ, Panel Members. Tailoring therapies – improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533-46.
- 6. Tan MH, Li J, Xu HE, Melcher K, Yong EL. Androgen receptor: Structure, role in prostate cancer, and drug discovery. Acta Pharmacol Sin. 2015;36:3-23.
- Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet. 1999;64:1371-7.

- Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015;14:769-78.
- 9. Thike AA, Chong LYZ, Cheok PY, Li HH, Yip GWC, Bay BH, Tse GMK, Iqbal J, Tan PH. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Modern Pathol. 2014;27:352-60.
- 10. Traina TA, Miller K, Yardley DA, O'Shaughnessy J, Cortes J, Awada A, Kelly CM, Trudeau ME, Schmid P, Gianni L, García-Estevez L, Nanda R, Ademuyiwa FO, Chan S, Steinberg JL, Blaney ME, Tudor IC, Uppal H, Peterson AC, Hudis CA. Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer. J Clin Oncol. 2015;33:1003.
- Zakaria F, El-Mashad N, Mohamed D: Androgen receptor expression as a prognostic and predictive marker in triplenegative breast cancer patients. Alexandria Journal of Medicine. 2016;52:131-40.
- 12. Isakoff SJ. Triple-negative breast cancer: Role of specific chemotherapy agents. Cancer J. 2010;16:53-61.
- 13. Laquente B, Viñals F, Germà JR. Metronomic chemotherapy: An antiangiogenic scheduling. Clin Transl Oncol. 2007;9:93-8.
- 14. Greenberg S, Rugo HS. Challenging clinical scenarios: Treatment of patients with triple-negative or basal-like metastatic breast cancer. Clin Breast Cancer. 2010;10(Suppl 2):S20-9.
- 15. Ohno S, Chow LWC, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, Nakayama T, Nakamura S, Kuroi K, Aogi K, Kashiwaba M, Yamashita H, Hisamatsu K, Ito Y, Yamamoto Y, Ueno T, Fakhrejahani E, Yoshida N, Toi M. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013;142:69-80.
- Abdelmaksoud BA, Mohamed A, Toam MM. A pilot study of extended adjuvant therapy with metronomic docetaxel for patients with operable triple-negative breast cancer. Asian Pac J Cancer. 2020;21:749-54.
- Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtiö J, Lewensohn R. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol. 2009;20:1639-46.
- Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010;2:205-12.
- 19. Farag K, Elfarargy O, Shorbagy SE, Ahmed S, Harb O, Amin R, Gertallah L, Megahed O, Abdel-latif R: Prevalence of androgen receptors expression in triple negative breast cancer patients and its correlation with clinicopathological criteria: Our Institutes experience. Journal of Clinical Oncology. 2017;35(15 suppl):e12584.

- 20. Pal S, Lüchtenborg M, Davies EA, Jack RH. The treatment and survival of patients with triple negative breast cancer in a London population. Springerplus. 2014;3:553.
- 21. Rodler E, Korde L, Gralow J. Current treatment options in triple negative breast cancer. Breast Dis. 2010;32:99-122.
- 22. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: Disease entity or title of convenience. Nat Rev Clin Oncol. 2010;7:683-92.
- 23. Chen X, Yu X, Chen J, Yang Z, Shao Z, Zhang Z, Guo X, Fenga Y. Radiotherapy can improve the disease-free survival rate in triple-negative breast cancer patients with T1-T2 disease and one to three positive lymph nodes after mastectomy. Oncologist. 2013;18:141-7.
- 24. Abdelaziz LA, Al Attar AZ, ElShorbagy S. Metronomic chemotherapy capecitabine in women with triple negative operable breast cancer. International Journal of Advanced Research. 2016;4:1103-14.
- 25. Alagizy HA, Shehata MA, Hashem TA, Abdelaziz KK, Swiha MM. Metronomic capecitabine as extend adjuvant chemotherapy in women with triple negative breast cancer. Hematol Oncol Stem Cell Ther. 2015;8:22-7.
- Gordon MA, D'Amato N, Gu H, Wong D, Elias A, Richer JK. Targeting multiple pathways in breast cancer: Androgen receptor, HER2, and mTOR. Cancer Res. 2014;75:P6-03-07.
- 27. Kriegsmann M, Endris V, Wolf T, Pfarr N, Stenzinger A, Loibl S, Denkert C, Schneeweiss A, Budczies J, Sinn P, Weichert W. Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget. 2014;5:9952-65.
- 28. Tung N, Garber JE, Hacker MR, Torous V, Freeman GJ, Poles E, Rodig S, Alexander B, Lee L, Collins LC, Schnitt SJ. Prevalence and predictors of androgen receptor (AR) and programmed death-ligand 1 (PD-L1) expression in BRCA1-associated and sporadic triple-negative breast cancer. J Clin Oncol. 2015;33: 1005.
- 29. Locatelli MA, Curigliano G, Eniu A. Extended adjuvant chemotherapy in triple-negative breast cancer. Breast Care. 2017;12:152-8.
- Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674-90.
- 31. Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA: PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16:406.
- Robles AJ, Cai S, Cichewicz RH, Mooberry SL. Selective activity of deguelin identifies therapeutic targets for androgen receptorpositive breast cancer. Breast Cancer Res Treat. 2016;157:475-88.